Posted by Michael Wonder on 30 Nov 2021
Schedule of Pharmaceutical Benefits - 1 December 2021
1 December 2021 - The December 2021 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The December issue of the Schedule includes a few new/revised listings:
- Follitropin alfa (Ovaleap) - new biosimilar medicine
- High fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate (KetoVie Peptide 4:1) - new formulation
- Lanadelumab (Takhzyro) - new medicine
- Ribavirin (Ibavyr) - new strength
- Ripretinib (Qinlock) - new medicine
- Venetoclax (Venclexta) - new indication
